1. Home
  2. AUPH vs ADV Comparison

AUPH vs ADV Comparison

Compare AUPH & ADV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AUPH
  • ADV
  • Stock Information
  • Founded
  • AUPH 1993
  • ADV 1987
  • Country
  • AUPH Canada
  • ADV United States
  • Employees
  • AUPH N/A
  • ADV N/A
  • Industry
  • AUPH Biotechnology: Pharmaceutical Preparations
  • ADV Business Services
  • Sector
  • AUPH Health Care
  • ADV Consumer Discretionary
  • Exchange
  • AUPH Nasdaq
  • ADV Nasdaq
  • Market Cap
  • AUPH 1.4B
  • ADV 586.7M
  • IPO Year
  • AUPH 1999
  • ADV N/A
  • Fundamental
  • Price
  • AUPH $12.30
  • ADV $1.86
  • Analyst Decision
  • AUPH Strong Buy
  • ADV Strong Buy
  • Analyst Count
  • AUPH 3
  • ADV 1
  • Target Price
  • AUPH $12.00
  • ADV $2.50
  • AVG Volume (30 Days)
  • AUPH 1.5M
  • ADV 591.8K
  • Earning Date
  • AUPH 11-06-2025
  • ADV 11-06-2025
  • Dividend Yield
  • AUPH N/A
  • ADV N/A
  • EPS Growth
  • AUPH N/A
  • ADV N/A
  • EPS
  • AUPH 0.42
  • ADV N/A
  • Revenue
  • AUPH $260,111,000.00
  • ADV $3,527,054,000.00
  • Revenue This Year
  • AUPH $16.92
  • ADV N/A
  • Revenue Next Year
  • AUPH $14.43
  • ADV N/A
  • P/E Ratio
  • AUPH $29.12
  • ADV N/A
  • Revenue Growth
  • AUPH 25.59
  • ADV N/A
  • 52 Week Low
  • AUPH $6.55
  • ADV $1.04
  • 52 Week High
  • AUPH $12.90
  • ADV $4.10
  • Technical
  • Relative Strength Index (RSI)
  • AUPH 56.77
  • ADV 54.34
  • Support Level
  • AUPH $12.06
  • ADV $1.77
  • Resistance Level
  • AUPH $12.90
  • ADV $2.05
  • Average True Range (ATR)
  • AUPH 0.39
  • ADV 0.10
  • MACD
  • AUPH -0.08
  • ADV -0.00
  • Stochastic Oscillator
  • AUPH 54.89
  • ADV 47.95

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

About ADV Advantage Solutions Inc.

Advantage Solutions Inc is a omnichannel retail solutions agency in North America, uniquely positioned at the intersection of consumer-packaged goods (CPG) brands and retailers.

Share on Social Networks: